{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000094","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.964320+00:00","generated_at":"2026-05-31T11:47:55.249159+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Editas Medicine Q2 2024 net loss $67.6M ($0.82/share), cash $318.3M, on track for clinical data by year-end","bullets":["Net loss $67.6M ($0.82 per share) vs $40.3M ($0.56 per share) in Q2 2023.","Cash and equivalents $318.3M as of June 30, 2024 (down from $376.8M Q1); runway into 2026.","R&D expenses $54.2M, up $24.4M driven by reni-cel program and in vivo research.","On track to present additional clinical data from RUBY (SCD) and EdiTHAL (TDT) trials by year-end 2024.","Completed enrollment of adult cohorts for both RUBY and EdiTHAL; adolescent cohort enrolled for RUBY."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000094","json":"https://secwatch.observer/filing/0001650664-24-000094.json","markdown":"https://secwatch.observer/filing/0001650664-24-000094.md","text":"https://secwatch.observer/filing/0001650664-24-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000094/0001650664-24-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000094/edit-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:47:55.249159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}